All In Biotech

Drug Trial Radar · NCT03943264

A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's

Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients With Alzheimer's Disease and Biomarkers of Inflammation.

Last checked: Nov 19, 2026Latest source record: Jun 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Nov 20, 2019

Primary completion

Jun 30, 2021

Study completion Sep 1, 2021

Sponsor

Lead sponsor
Inmune Bio, Inc.Industry
Sponsor type
Industry
Collaborators
Alzheimer's Association
First posted
May 9, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate safety and target engagement of XPro1595 in Alzheimer's patients with biomarkers of inflammation.

Conditions

  • Alzheimer Disease

Interventions

  • XPro1595Drug

    XPro1595 will be delivered by subcutaneous injection once a week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of patients with a treatment-emergent adverse event throughout 12 weeks of treatment with XPro1595Time frame: 12 weeks
  2. The percentage of patients with a treatment-emergent adverse event throughout 12 weeks of treatment with XPro1595Time frame: 12 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • KaRa MINDS

    Macquarie Park, New South Wales, Australia

  • Mater Medical Research Institute

    Brisbane, Queensland, Australia

  • Central Adelaide Local Health Network

    Woodville, South Australia, Australia

  • Alfred Heath

    Melbourne, Victoria, Australia

  • Eastern Clinical Research Unit

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.